Browse All

Current Filters

CLEAR FILTER x

TITLE

Title
    Author Last Name
      Session Name
        Topic
          Program Number
            Author Institution

              NfL as a Predictor of GdE Lesions in Patients With Relapsing Multiple Sclerosis Treated With Ozanimod in the Phase 2 RADIANCE Trial

              Author:Harris, Sarah   Vermersch, Patrick   Montalban, Xavier   Hartung, Hans-Peter   Kappos, Ludwig   Southworth, Harry   Sheffield, James K.   Silva, Diego   Cohen, Jeffrey A.   

              Session Name:P1: MS Biomarkers  

              Topic:MS and Inflammatory Disease  

              Program Number:P1.012  

              Author Institution:Bristol Myers Squibb, Princeton, New Jersey, Princeton, NJ  Univ. Lille, Inserm UMR U1172, CHU Lille, FHU Precise, Lille, France, Lille, France  Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona, Spain, Barcelona, Spain  Department of Neurology, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany  Brain and Mind Centre, University of Sydney, Sydney, Australia  Department of Neurology, Medical University of Vienna, Vienna, Austria  and Palacký University Olomouc, Olomouc, Czech Republic, Olomouc, Czech Republic  Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Head, Spine and Neuromedicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland, Basel, Switzerland  Data Clarity Consulting Ltd, Stockport, England, United Kingdom, England, United Kingdom  Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, Ohio, Cleveland, OH  

              Correlations Between Early MRI Parameters and Long-term Clinical Outcomes in Phase 3 and Open-label Extension Studies of Ozanimod in Relapsing Multiple Sclerosis

              Author:Arnold, Douglas L.   Freeman, Leorah   Hartung, Hans-Peter   Montalbán, Xavier   Cohen, Jeffrey A.   Bar-Or, Amit   Steinman, Lawrence   DeLuca, John   Cheng, Chun-Yen   Riolo, Jon V.   Silva, Diego   Pachai, Chahin   Cree, Bruce A. C.   

              Session Name:P5: MS Prognosis/Epidemiology  

              Topic:MS and Inflammatory Disease  

              Program Number:P5.010  

              Author Institution:NeuroRx Research and Montréal Neurological Institute, McGill University, Montréal, Quebec, Canada, Montréal, QC, Canada  Dell Medical School, The University of Texas at Austin, Austin, Texas, Austin, TX  Department of Neurology, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany  Brain and Mind Centre, University of Sydney, Australia  Department of Neurology, Medical University of Vienna, Austria  and Palacký University Olomouc, Olomouc, Czech Republic, Olomouc, Czech Republic  Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona, Spain, Barcelona, Spain  Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, Ohio, Cleveland, OH  Center for Neuroinflammation and Experimental Therapeutics, and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, Philadelphia, PA  Department of Neurology and Neurological Sciences, Beckman Center for Molecular Medicine, Stanford University Medical Center, Stanford, California, Stanford, CA  Kessler Foundation, West Orange, New Jersey, and Departments of Physical Medicine and Rehabilitation, and Neurology, Rutgers - New Jersey Medical School, Newark, New Jersey, Newark, NJ  Bristol Myers Squibb, Princeton, New Jersey, Princeton, NJ  Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, California, San Francisco, CA